
|Articles|May 18, 2020
Dr. Lemack on treatments in development for OAB
In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.
Advertisement
Gary Lemack, MD, of UT Southwestern Medical Center in Dallas, co-authored an
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
5











